Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chinook Therapeutics Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes medicines for rare, severe chronic kidney diseases. It's pipeline products include atrasentan treats IgA Nephropathy, basket of glomerular diseases; Zigakibart (Bion- 1301) for the treatment of IgA Nephropathy; CHK-336 for idiopathic hyperoxaluria; research and discovery programs targets rare, severe chronic kidney diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.
Headquarters
United States of America
Address
188 E Blaine Street, Suite 126, Seattle, Washington, 98109
Website
www.chinooktx.com
No of Employees
214
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$6.1M
Chinook Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Atrasentan: IgA Nephropathy, Basket of Glomerular Diseases |
| Bion- 1301: IgA Nephropathy |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Chinook Therapeutics Inc | Lumos Pharma Inc | Aceragen Inc | XORTX Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Canada |
| City | Seattle | Austin | Durham | Calgary |
| State/Province | Washington | Texas | North Carolina | Alberta |
| No. of Employees | 214 | 30 | - | 3 |
| Entity Type | Private | Private | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Eric Dobmeier | Chief Executive Officer; President | Executive Board | 2019 | 55 |
| Eric Bjerkholt | Chief Financial Officer | Senior Management | 2020 | 64 |
| Tom Frohlich | Chief Operating Officer | Senior Management | 2019 | 48 |
| Andrew King, BVMS, Ph.D | Chief Scientific Officer | Senior Management | 2021 | 45 |
| Andrew King | Chief Scientific Officer | Senior Management | 2019 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer